Wendy Stock, MD, focuses on treatment for patients with acute and chronic leukemias, myelodysplastic syndromes and myeloproliferative neoplasms, including hematopoietic cell therapies. Her focus has been to design biologically risk-adapted clinical trials for patients with acute leukemias, leading national trials for treatment of acute lymphoblastic leukemia (ALL) that have helped to change the standard of care for young adults with this disease. Dr. Stock has also established a young adult leukemia clinic which is committed to providing innovative research trials and clinical care to this patient population.
She has focused on identifying new biological prognostic factors in specific subsets of leukemia that lead to novel clinical trial design and has focused particularly on the clinical significance of molecular detection and monitoring of subclinical disease (or minimal residual disease) using quantitative molecular methods. Her laboratory uses preclinical models to evaluate novel treatment strategies that might translate to the clinic to overcome treatment resistance and enhance minimal residual disease eradication.
Dr. Stock currently is co-chair of the Leukemia Committee for the National Cancer Institute-supported Alliance for Clinical Trials in Oncology and a co-leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center. She also serves as an Associate Editor for Blood Advances and is a Councillor for the American Society of Hematology.
